Astrocytomasarethemostcommonprimary brain tumors in both children and adults. They are classified by grade based on such features as the presence of mitoses, necrosis, hypercellularity, nuclear and cytoplasmic atypia, and endothelial proliferation within the tumor. The identification of the genetic alterations commonly found in astrocytomas has led to the recognition that there may be a sequential series of genetic changesthatareoftentimes, althoughclearly not always, associated with the enhanced degree of malignancy corresponding to increased clinical grade ( Figure) . In order of increasing malignancy, other astrocytic tumors are classified as astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme (GBM). Pilocytic astrocytomas are of a particularly low histological grade and are frequently cured by surgery.
A tumor suppressor gene frequently implicated in the pathogenesis of astrocytoma is p53, located on chromosome 17p. 1 The p53 protein has been found to influence multiple cellular functions including progression through the cell cycle, DNA repair after damage, genomic stability, and the tendency for a cell to undergo apoptosis following treatment. p53 Acts as a transcription factor to induce or repress the transcription of multiple genes through sequence-specific interaction with DNA. p53 mutations have been reported in approximately 40% of astrocytic tumors of all grades. These are found most commonly in gliomas occurring in young adults. In contrast, p53 mutations have not been observed in supratentorial astrocytic tumors of children, although they occur in brainstem gliomas of childhood. The prognostic implication of p53 mutations has not yet been defined clearly. It remains a strong candidate for being clinically significant, since p53 mediates the response of tumors to irradiation, which is an important modality of treatment for these tumors. 8 Another tumor suppressor gene frequently inactivated in astrocytic neoplasms is CDKN2, which encodes p16. p16 Binds to and inhibits the function of the cyclindependent kinase CDK4. Complexed with cyclin D proteins, CDK4 inhibits pRB, the protein product of the tumor suppressor gene RB1 (located on chromosome 13q) and results in loss of RB1-mediated growth suppression. Inactivation of the CDKN2 gene, located on chromosome 9p, appears most commonly to result from deletion of both copies of the gene. This mutation occurs frequently in highgrade astrocytomas. Loss of CDKN2 is an uncommon event in low-grade astrocytomas. Since both p16 and pRB appear to inhibit cell cycle progression through the same pathway, it is possible that defects in both p16 and RB may convey no additional growth advantage to a cell over that resulting from mutation of either p16 or RB alone. This interpretation is compatible with the observation that most GBMs have a defect in either p16 or RB, although both genes are rarely inactivated in the same tumor. 2 Interestingly, GBMs that do not have mutated p16 or RB have been found to have amplification of CDK4, a third mechanism by which the function of this critical pathway for cell growth regulation can be inhibited.
Deletions of chromosome 10 occur frequently in astrocytic tumors, and there is considerable evidence for the presence of multiple tumor suppression genes on chromosome 10. 3 Loss of heterozygosity at 10q23 has been reported to occur in as many as 70% of glioblastomas. MMAC, a tumor suppression gene also known as PTEN or TEP1 and located at 10q, has been found to be mutated in 40% of glioblastomas. MMAC encodes a protein that has phosphatase activity and causes growth suppression in vitro and in vivo. MMAC alterations, as well as alterations in genes known to be important in cell cycle regulation, are seen in GBM that arise without evidence of a precursor lesion as well as in GBM that arise as the result of progressive genetic changes occurring in lowergrade astrocytic tumors. 4 Since mutations of MMAC are rarely found in low-grade gliomas, this gene may be important for the progression to more malignant, highgrade tumors (Figure) .
Pilocytic astrocytomas are generally benign and occur most frequently in the cerebellum or optic nerve of children. They usually do not progress to more malignant, high-grade tumors. Patients with neurofibromatosis type 1, which results from inactivation of the NF1 gene, have an increased frequency of pilocytic astrocytomas. Also, 20% of spontaneous pilocytic astrocytomas have a deletion of chromosome 17q (the location of the NF1 gene), although structural analysis of the NF1 gene in these tumors has not yet been reported. Deletion or mutation of the p53 locus is rare in pilocytic astrocytomas, although deletion of loci on chromosome 17p (the location of the p53 locus) has been reported in a small number of pilocytic astrocytomas. A second tumor suppressor locus on this chromosomal arm may be important in the pathogenesis of these tumors. Gains of chromosomes 7 and 8 have also been noted in some pilocytic astrocytomas.
In contrast to tumor suppressor gene mutations that result in the loss of function of proteins key for the inhibition of cell proliferation, the activation of oncogenes results in enhanced function leading to increased cell proliferation. Amplification is a frequent mechanism by which oncogenes are activated. Gene amplification is a manifestation of genetic instability, an important characteristic of many if not all cancers. Recently, the development of a new technology, comparative genomic hybridization, which characterizes the copy number of long stretches of DNA along tumor cell chromosomes, has led to the recognition that there is much more gene amplification in astrocytic brain tumors than previously appreciated. 5 The EGFR (epidermal growth factor receptor) gene is the gene most frequently found to be amplified in malignant astrocytomas. 6 EGFR encodes a protein that functions as a receptor for the epidermal growth factor, an important growth stimulant for astrocytes. Amplification of a mutated EGFR allele is infrequently found in low-grade astrocytomas but is detectable in about one third of glioblastomas, especially those occurring in elderly patients. Numerous other genes have been found to be amplified occasionally in individual astrocytic tumors, but few have been found to be frequently affected. These include CDK4 and MDM2 that are amplified in approximately 10% to 15% of astrocytic tumors. Point mutations that result in the expression of an activated gene product have only rarely been reported. Recently recognized chromosomal regions frequently amplified in high-grade astrocytomas and in which no known oncogenes are located include 1q, 9q, and 12q.
OLIGODENDROGLIOMA
Oligodendrogliomas are uncommon gliomas (Ͻ10% of all intracranial tumors) that appear to arise from oligodendroglial cells. Cytogenetic studies have indicated that the genetic alterations associated with these tumors are distinctive from those that are found in astrocytic tumors. Oligodendrogliomas characteristically exhibit a loss of chromosomal regions on 1p and 19q13. 7 Other chromosomal regions sometimes lost from oligodendrogliomas include 1p36, 9p, and 22, and there is frequently evidence of increased numbers of chromosome 7 in these tumors. Other molecular genetic events common in astrocytic tumors seem to be rare in oligodendrogliomas: p53 mutations and EGFR amplification are almost never present. LOH for chromosome 9p loci, observed in some oligodendrogliomas, suggests the possible loss of the p16 locus.
MENINGIOMAS
Meningiomas are tumors that arise from the dura, the membrane that encloses the brain, and are almost invariably benign. Elderly patients are more frequently affected and women more often than men. Patients with neurofibromatosis type 2 may be affected by multiple meningiomas and bilateral vestibular schwannomas. The gene that encodes the propensity of patients to develop neurofibromatosis type 2, NF2, is located on chromosome 22q12. The protein product of the NF2 gene, known as merlin, is a cytoskeletal protein. Most reported NF2 mutations to date predict a truncated protein product. Deletion of loci on chromosome 22q occurs in approximately 30% of sporadic meningiomas, suggesting a role for NF2 in their development. Interestingly, mutations in NF2 are not found in dural hemangiopericytomas, a tumor sometimes considered a variant of classic menigioma. Amplification or high level expression of oncogenes and deletion or mutation of p53 appear to be infrequent events in meningioma. One exception may be expression of the ROS1 receptor tyrosine kinase oncogene, which has been reported in as many as 55% of meningiomas. Malignant meningiomas may be associated with deletion of loci on chromosome 1p and less commonly on 6p, 9q, 10q, 14q, and 17p. p53 mutations have also been reported in malignant meningioma.
PRIMITIVE NEUROECTODERMAL TUMORS
Primitive neuroectodermal tumors typically appear histologically as sheets of small round malignant cells with scant cytoplasm, and include a number of different pathologic entities that usually present during childhood. The most common chromosomal alteration in primitive neuroectodermal tumors is isochrome (17q). Medulloblastomas are primitive neuroectodermal tumors that arise in the cerebellum, and these tumors occur in 2 inherited cancer syndromes, Turcot syndrome and basal cell nevus syndrome. Turcot syndrome is characterized by germline mutations of the APC gene in patients with adenomatous polyposis coli. Somatic mutations of APC have not been detected in sporadically occurring medulloblastomas; however, infrequent mutations of the ␤-catenin gene, which encodes a protein that interacts with the APC gene product in medulloblastomas, suggest strongly that this pathway is important in the pathogenesis of this tumor. Patients with basal cell nevus syndrome carry germline mutations of the PTCH gene at 9q22.3-9q31 and can develop medulloblastoma. Mutation of PTCH is also occasionally found in sporadic medulloblastoma, especially desmoplastic medulloblastoma. 9 Cytogenetic studies of medulloblastomas have identified chromosome 17p as a frequent site of deletions, but this seems to involve a site telomeric to p53 at 17p13. p53 Is rarely mutated in these tumors. Other molecular genetic changes sometimes found in medulloblastomas are deletions of chromosomes 2p, 6q, 8p, 10q, 11p, 11q, and 16q and rare amplifications of CMYC. Less information is available about primitive neuroectodermal tumors of the cerebral hemispheres and ependymomas, a related tumor that can be easily distinguished by its rather characteristic appearance. The most commonly described genetic alterations in ependymomas are deletions of 17p and monosomy 22.
